Quidel Corporation Appoints Renowned Experts in Reproductive Health to Advisory Board; Erudite Panel Rounds out Company's Clinical Expertise

In addition to women's health issues, such as infectious vaginitisand sexually transmitted diseases, the panel's expertise extends toother important fields of bone health and oncology. The board willinitially be charged with a review of Quidel's current reproductivehealth portfolio to determine if there could be other applications forexisting products, in addition to gaining greater insight into marketopportunities for future product development. Additional goals includehelping Quidel identify and support relevant clinical researchefforts.

"We are honored that these illustrious experts see the value ofour Reproductive Health Advisory Board and are investing the time andcommitment to advance the development and adoption of rapid diagnosticsolutions in this important area of healthcare," said Caren Mason,president and chief executive officer of Quidel Corporation. "Asambassadors in the field of reproductive health, the panel will alsoprovide valuable insight into clinicians' attitudes towardspoint-of-care testing in general, and, more specifically, provideinput and expertise as we work to expand our portfolio of products toprovide solutions that address the full spectrum of care both ininfectious disease and reproductive health."

Chaired by David Soper, M.D. from the Medical University of SouthCarolina, the board also includes:

-- Daron G. Ferris, M.D., Medical College of Georgia

-- Megan Gerber, M.D., MPH, Harvard Medical School

-- Patti Gravitt, Ph.D., Bloomberg School of Public Health, Johns Hopkins University

-- Sharon Hillier, Ph.D., Magee-Women's Hospital, University of Pittsburgh

-- Mary Jacobsen, M.D., Stanford University Medical Center

-- Jeanne Marrazzo, M.D., MPH, University of Washington

-- Frank Miller, M.D., University of Kentucky, past president of ACOG

-- Paul Nyirjesy, M.D., Drexel University College of Medicine

-- Jane Schwebke, M.D., University of Alabama at Birmingham

-- Rosemary "Mimi" Clarke Secor, nurse practitioner, The Center For Women's Health

-- Jack D. Sobel, M.D., Detroit Medical Center

-- Harold Wiesenfeld, M.D., University of Pittsburgh

-- Jonathan M. Zenilman, M.D., Johns Hopkins School of Medicine

About Quidel Corp.

Quidel Corporation serves to enhance the health and well being ofpeople around the globe through the discovery, development,manufacturing and marketing of rapid diagnostic solutions at the pointof care (POC) in infectious diseases and reproductive health. Marketedunder the leading brand name of QuickVue(R), the portfolio currentlyincludes tests that aid in the diagnosis of several disease orcondition states, including influenza, Strep A, pregnancy, bacterialvaginosis, infectious mononucleosis, H. pylori and chlamydia. Quidel'sproducts are sold to healthcare professionals with a focus on thephysician office lab and acute care markets through leading medicaldistribution partners on a worldwide basis. Quidel's SpecialtyProducts Group (SPG) develops research products in the fields ofoncology and bone health with future point-of-care applications. Bybuilding value in rapid diagnostic tests, Quidel provides leadershipto the industry and among healthcare professionals allowing for themovement of patient testing out of the central laboratory setting andinto the physician office, urgent care and other outpatient settingswhere rapid testing and treatment has an impact on clinical outcomesand provides an economic benefit. For more information, visitwww.quidel.com.

This press release contains forward-looking statements within themeaning of the federal securities laws that involve material risk anduncertainties. Many possible events or factors could affect our futurefinancial results and performance, such that our actual results andperformance may differ materially. As such, no forward-lookingstatement can be guaranteed. Differences in operating results mayarise as a result of a number of factors including, withoutlimitation, seasonality, adverse changes in the competitive andeconomic conditions in domestic and international markets, actions ofour major distributors, manufacturing and production delays ordifficulties, adverse actions or delays in product reviews by the U.S.Food and Drug Administration ("FDA"), intellectual property, productliability, environmental or other litigation, and the lower acceptanceof our new products than forecast. Forward-looking statementstypically are identified by the use of terms such as "may," "will,""should," "might," "expect," "anticipate," "estimate" and similarwords, although some forward-looking statements are expresseddifferently. The risks described under "Risk Factors" in reports andregistration statements that we file with the SEC from time to timeshould be carefully considered. You are cautioned not to place unduereliance on these forward-looking statements, which reflectmanagement's analysis only as of the date of this press release. Weundertake no obligation to publicly release the results of anyrevision of the forward-looking statements.